BTIG Downgrades Checkmate Pharmaceuticals (CMPI) to Neutral on Takeover
Tweet
Share
E-mailGet Alerts CMPI Hot Sheet
Price: $10.50 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
BTIG analyst Kaveri Pohlman downgraded Checkmate Pharmaceuticals (NASDAQ: CMPI) from Buy to Neutral after the company agreed to be acquired by Regeneron.
For an analyst ratings summary and ratings history on Checkmate Pharmaceuticals click here. For more ratings news on Checkmate Pharmaceuticals click here.
Shares of Checkmate Pharmaceuticals closed at $10.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Double Downgrades Mosaic (MOS) to Sell
- Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
- Legence Corp (LGN) PT Lowered to $100 at BTIG
Create E-mail Alert Related Categories
DowngradesRelated Entities
BTIGSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
